Q-omics provides the consensus-scored TRMT11 profile across patient tissues and cancer cell-line models. TRMT11 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, TRMT11 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TRMT11 RNA expression shows 20,333 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight CESC, HNSC, and UVM as cancer lineages where TRMT11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRMT11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRMT11 survival associations across molecular data types. TRMT11 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRMT11 RNA expression–survival associations across cancer types. High TRMT11 expression shows unfavorable associations in CESC, HNSC, KIRC, SCLC and KICH, but favorable associations in SKCM. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify CESC as the clearest survival context for TRMT11 RNA expression.
This table summarizes TRMT11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TRMT11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRMT11 shows lower tumor expression in KICH and BRCA and higher tumor expression in HNSC, COAD, STAD and READ. The HNSC box plot shows higher TRMT11 RNA expression in tumor versus normal tissue (log2 FC = +0.924, t-test p < 0.001).
This table shows molecular features associated with TRMT11 in patient tissues and cancer cell lines. In patient samples, TRMT11 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRMT11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
